Hepatitis B virus infection and renal transplantation

World Journal of Gastroenterology

Volumn 16, Issue 31, 2010, Pages 3878-3887

  Tsai, Ming Chao ^a   Chen, Yen Ta ^a   Chien, Yu Shu ^a   Chen, Te Chuan ^a   Hu, Tsung Hui ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Hepatitis B; Lamivudine resistance; Renal transplantation

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; PEGINTERFERON; TELBIVUDINE; TENOFOVIR; VIRUS DNA;

ACUTE GRAFT REJECTION; DISEASE COURSE; DONOR SELECTION; FOLLOW UP; GRAFT SURVIVAL; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; KIDNEY TRANSPLANTATION; LIVER BIOPSY; MORBIDITY; MORTALITY; NEPHROTOXICITY; REVIEW; VIRUS REPLICATION; VIRUS TRANSMISSION;

EID: 77955979543     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v16.i31.3878     Document Type: Review

References (100)

1. Fabrizi F, Lunghi G, Poordad FF, Martin P. Management of hepatitis B after renal transplantation: an update. J Nephrol 2002; 15: 113-122.
2. Fabrizi F, Martin P, Dixit V, Kanwal F, Dulai G. HBsAg seropositive status and survival after renal transplantation: meta-analysis of observational studies. Am J Transplant 2005; 5: 2913-2921.
3. Mathurin P, Mouquet C, Poynard T, Sylla C, Benalia H, Fretz C, Thibault V, Cadranel JF, Bernard B, Opolon P, Coriat P, Bitker MO. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999; 29: 257-263.
4. Lee WC, Shu KH, Cheng CH, Wu MJ, Chen CH, Lian JC. Long-term impact of hepatitis B, C virus infection on renal transplantation. Am J Nephrol 2001; 21: 300-306.
5. Diethelm AG, Deierhoi MH, Hudson SL, Laskow DA, Julian BA, Gaston RS, Bynon JS, Curtis JJ. Progress in renal transplantation. A single center study of 3359 patients over 25 years. Ann Surg 1995; 221: 446-457; discussion 457-458.
6. Starzl TE, Weil R 3rd, Iwatsuki S, Klintmalm G, Schröter GP, Koep LJ, Iwaki Y, Terasaki PI, Porter KA. The use of cyclosporin A and prednisone in cadaver kidney transplantation. Surg Gynecol Obstet 1980; 151: 17-26.
7. Santos L, Alves R, Macario F, Parada B, Campos M, Mota A. Impact of hepatitis B and C virus infections on kidney transplantation: a single center experience. Transplant Proc 2009; 41: 880-882.
8. Morales JM, Domínguez-Gil B, Sanz-Guajardo D, Fernández J, Escuin F. The influence of hepatitis B and hepatitis C virus infection in the recipient on late renal allograft failure. Nephrol Dial Transplant 2004; 19 Suppl 3: iii72-iii76.
9. Tsai MC, Chen CH, Lee CM, Chen YT, Chien YS, Hung CH, Wang JH, Lu SN, Yen YH, Changchien CS, Hu TH. The role of HBV genotype, core promoter and precore mutations in advanced liver disease in renal transplant recipients. J Hepatol 2009; 50: 281-288.
10. Hu RH, Lee PH, Chung YC, Huang MT, Lee CS. Hepatitis B and C in renal transplantation in Taiwan. Transplant Proc 1994; 26: 2059-2061.
11. Wolf JL, Perkins HA, Schreeder MT, Vincenti F. The transplanted kidney as a source of hepatitis B infection. Ann Intern Med 1979; 91: 412-413.
12. Lutwick LI, Sywassink JM, Corry RJ, Shorey JW. The transmission of hepatitis B by renal transplantation. Clin Nephrol 1983; 19: 317-319.
13. Sumethkul V, Ingsathit A, Jirasiritham S. Ten-year followup of kidney transplantation from hepatitis B surface antigen-positive donors. Transplant Proc 2009; 41: 213-215.
14. Berber I, Aydin C, Yigit B, Turkmen F, Titiz IM, Altaca G. The effect of HBsAg-positivity of kidney donors on longterm patient and graft outcome. Transplant Proc 2005; 37: 4173-4175.
15. Jiang H, Wu J, Zhang X, Wu D, Huang H, He Q, Wang R, Wang Y, Zhang J, Chen J. Kidney transplantation from hepatitis B surface antigen positive donors into hepatitis B surface antibody positive recipients: a prospective nonrandomized controlled study from a single center. Am J Transplant 2009; 9: 1853-1858.
16. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009; 373: 582-592.
17. Fornairon S, Pol S, Legendre C, Carnot F, Mamzer-Bruneel MF, Brechot C, Kreis H. The long-term virologic and pathologic impact of renal transplantation on chronic hepatitis B virus infection. Transplantation 1996; 62: 297-299.
18. Degos F, Lugassy C, Degott C, Debure A, Carnot F, Theirs V, Tiollais P, Kreis H, Brechot C. Hepatitis B virus and hepatitis B-related viral infection in renal transplant recipients. A prospective study of 90 patients. Gastroenterology 1988; 94: 151-156.
19. Parfrey PS, Forbes RD, Hutchinson TA, Kenick S, Farge D, Dauphinee WD, Seely JF, Guttmann RD. The impact of renal transplantation on the course of hepatitis B liver disease. Transplantation 1985; 39: 610-615.
20. Aroldi A, Lampertico P, Montagnino G, Passerini P, Villa M, Campise MR, Lunghi G, Tarantino A, Cesana BM, Messa P, Ponticelli C. Natural history of hepatitis B and C in renal allograft recipients. Transplantation 2005; 79: 1132-1136.
21. Blanpain C, Knoop C, Delforge ML, Antoine M, Peny MO, Liesnard C, Vereerstraeten P, Cogan E, Adler M, Abramowicz D. Reactivation of hepatitis B after transplantation in patients with pre-existing anti-hepatitis B surface antigen antibodies: report on three cases and review of the literature. Transplantation 1998; 66: 883-886.
22. Marcellin P, Giostra E, Martinot-Peignoux M, Loriot MA, Jaegle ML, Wolf P, Degott C, Degos F, Benhamou JP. Redevelopment of hepatitis B surface antigen after renal transplantation. Gastroenterology 1991; 100: 1432-1434.
23. Grotz W, Rasenack J, Benzing T, Berthold H, Peters T, Walter E, Schollmeyer P, Rump LC. Occurrence and management of hepatitis B virus reactivation following kidney transplantation. Clin Nephrol 1998; 49: 385-388.
24. Rivolta E, De Vecchi A, Tarantino A, Castelnovo C, Berardinelli L, Ponticelli C. Prognostic significance of hepatitis B surface antigenemia in cadaveric renal transplant patients. Transplant Proc 1987; 19: 2153-2154.
25. Flagg GL, Silberman H, Takamoto SK, Berne TV. The influence of hepatitis B infection on the outcome of renal allotransplantation. Transplant Proc 1987; 19: 2155-2158.
26. Berne TV, Fitzgibbons TJ, Silberman H. The effect of hepatitis B antigenemia on long-term success and hepatic disease in renal transplant recipients. Transplantation 1977; 24: 412-415.
27. Huang CC, Lai MK, Fong MT. Hepatitis B liver disease in cyclosporine-treated renal allograft recipients. Transplantation 1990; 49: 540-544
28. Paparella M, Tarantino A, Ponticelli C. How to manage the dialysis patient with chronic viral hepatitis who is considered for renal transplantation. Nephrol Dial Transplant 1996; 11: 2122-2124.
29. Breitenfeldt MK, Rasenack J, Berthold H, Olschewski M, Schroff J, Strey C, Grotz WH. Impact of hepatitis B and C on graft loss and mortality of patients after kidney transplantation. Clin Transplant 2002; 16: 130-136.
30. Chan TM, Fang GX, Tang CS, Cheng IK, Lai KN, Ho SK. Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients. Hepatology 2002; 36: 1246-1252.
31. London WT, Drew JS, Blumberg BS, Grossman RA, Lyons PJ. Association of graft survival with host response to hepatitis B infection in patients with kidney transplants. N Engl J Med 1977; 296: 241-244.
32. Liaw YF. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. Liver Int 2009; 29 Suppl 1: 100-107.
33. Fairley CK, Mijch A, Gust ID, Nichilson S, Dimitrakakis M, Lucas CR. The increased risk of fatal liver disease in renal transplant patients who are hepatitis Be antigen and/or HBV DNA positive. Transplantation 1991; 52: 497-500.
34. Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000; 118: 554-559.
35. Lee CM, Chen CH, Lu SN, Tung HD, Chou WJ, Wang JH, Chen TM, Hung CH, Huang CC, Chen WJ. Prevalence and clinical implications of hepatitis B virus genotypes in southern Taiwan. Scand J Gastroenterol 2003; 38: 95-101.
36. Kao JH. Role of viral factors in the natural course and therapy of chronic hepatitis B. Hepatol Int 2007; 1: 415-430.
37. Chu SH, Chen Y, Chiang YJ, Huang CC. Older recipients who are carriers of hepatitis B and/or C and the outcome of renal transplantation. Transplant Proc 2000; 32: 1946-1948.
38. Aroldi A, Lampertico P, Montagnino G, Lunghi G, Passerini P, Villa M, Campise M, Cesana BM, Ponticelli C. Natural history of hepatitis C virus infection in adult renal graft recipients. Transplant Proc 2005; 37: 940-941.
39. Chen CH, Lee CM, Lu SN, Changchien CS, Eng HL, Huang CM, Wang JH, Hung CH, Hu TH. Clinical significance of hepatitis B virus (HBV) genotypes and precore and core promoter mutations affecting HBV e antigen expression in Taiwan. J Clin Microbiol 2005; 43: 6000-6006.
40. Lindh M, Hannoun C, Dhillon AP, Norkrans G, Horal P. Core promoter mutations and genotypes in relation to viral replication and liver damage in East Asian hepatitis B virus carriers. J Infect Dis 1999; 179: 775-782.
41. Kao JH, Chen PJ, Lai MY, Chen DS. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology 2003; 124: 327-334.
42. Günther S, Baginski S, Kissel H, Reinke P, Krüger DH, Will H, Meisel H. Accumulation and persistence of hepatitis B virus core gene deletion mutants in renal transplant patients are associated with end-stage liver disease. Hepatology 1996; 24: 751-758.
43. Preikschat P, Günther S, Reinhold S, Will H, Budde K, Neumayer HH, Krüger DH, Meisel H. Complex HBV populations with mutations in core promoter, C gene, and pre-S region are associated with development of cirrhosis in longterm renal transplant recipients. Hepatology 2002; 35: 466-477.
44. Harnett JD, Zeldis JB, Parfrey PS, Kennedy M, Sircar R, Steinmann TI, Guttmann RD. Hepatitis B disease in dialysis and transplant patients. Further epidemiologic and serologic studies. Transplantation 1987; 44: 369-376.
45. Rao KV, Kasiske BL, Anderson WR. Variability in the morphological spectrum and clinical outcome of chronic liver disease in hepatitis B-positive and B-negative renal transplant recipients. Transplantation 1991; 51: 391-396.
46. Ahn HJ, Kim MS, Kim YS, Kim SI, Huh KH, Ju MK, Ahn SH, Han KH. Clinical outcome of renal transplantation in patients with positive pre-transplant hepatitis B surface antigen. J Med Virol 2007; 79: 1655-1663.
47. Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007; 45: 1056-1075.
48. Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, Häussinger D. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996; 334: 1422-1427.
49. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, Fried MW, Chow WC, Paik SW, Chang WY, Berg T, Flisiak R, McCloud P, Pluck N. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682-2695.
50. Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999; 29: 971-975.
51. van Zonneveld M, Honkoop P, Hansen BE, Niesters HG, Darwish Murad S, de Man RA, Schalm SW, Janssen HL. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 2004; 39: 804-810.
52. Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, Chen Y, Heathcote EJ, Rasenack J, Bzowej N, Naoumov NV, Di Bisceglie AM, Zeuzem S, Moon YM, Goodman Z, Chao G, Constance BF, Brown NA. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357: 2576-2588.
53. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, DeHertogh D, Wilber R, Zink RC, Cross A, Colonno R, Fernandes L. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 1011-1020.
54. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662.
55. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, Jeffers L, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CL. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808-816.
56. Gish RG, Lok AS, Chang TT, de Man RA, Gadano A, Sollano J, Han KH, Chao YC, Lee SD, Harris M, Yang J, Colonno R, Brett-Smith H. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007; 133: 1437-1444.
57. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Ma J, Brosgart CL, Borroto-Esoda K, Arterburn S, Chuck SL. Long-term therapy with adefovir dipivoxil for HBeAgnegative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131: 1743-1751.
58. Chang TT, Lai CL, Kew Yoon S, Lee SS, Coelho HS, Carrilho FJ, Poordad F, Halota W, Horsmans Y, Tsai N, Zhang H, Tenney DJ, Tamez R, Iloeje U. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010; 51: 422-430.
59. Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, Wichroski MJ, Xu D, Yang J, Wilber RB, Colonno RJ. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology 2009; 49: 1503-1514.
60. Peters M. Mechanisms of action of interferons. Semin Liver Dis 1989; 9: 235-239.
61. Taylor JL, Grossberg SE. The effects of interferon-alpha on the production and action of other cytokines. Semin Oncol 1998; 25: 23-29.
62. Kuhen KL, Samuel CE. Mechanism of interferon action: functional characterization of positive and negative regulatory domains that modulate transcriptional activation of the human RNA-dependent protein kinase Pkr promoter. Virology 1999; 254: 182-195.
63. Post AB, Hricik DE, Sterling RK, Bartucci MR, Jacobs GH, Schulak JA. Resolution of hepatitis B viremia in a renal transplant recipient treated with alpha-2b interferon. Nephron 1998; 79: 469-471.
64. Grotz W, Gondolf K, Rasenack J, Berthold H, Rump LC, Schollmeyer P. Imminent liver failure in a hepatitis-Bpositive renal-allograft recipient: successful therapy with interferon-alpha. Nephrol Dial Transplant 1995; 10: 1932-1934.
65. Durlik M, Gaciong Z, Rancewicz Z, Rowinska D, Wyzgal J, Kozlowska B, Gradowska L, Lao M, Nowaczyk M, Korczak-Kowalska G. Renal allograft function in patients with chronic viral hepatitis B and C treated with interferon alpha. Transplant Proc 1995; 27: 958-959.
66. Kovarik J, Mayer G, Pohanka E, Schwarz M, Traindl O, Graf H, Smolen J. Adverse effect of low-dose prophylactic human recombinant leukocyte interferon-alpha treatment in renal transplant recipients. Cytomegalovirus infection prophylaxis leading to an increased incidence of irreversible rejections. Transplantation 1988; 45: 402-405.
67. Rostaing L, Izopet J, Baron E, Duffaut M, Puel J, Durand D. Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients. Transplantation 1995; 59: 1426-1431.
68. Magnone M, Holley JL, Shapiro R, Scantlebury V, McCauley J, Jordan M, Vivas C, Starzl T, Johnson JP. Interferonalpha-induced acute renal allograft rejection. Transplantation 1995; 59: 1068-1070.
69. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, Crowther L, Condreay LD, Woessner M, Rubin M, Brown NA. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 1256-1263.
70. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL, Gray DF. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339: 61-68.
71. Grellier L, Mutimer D, Ahmed M, Brown D, Burroughs AK, Rolles K, McMaster P, Beranek P, Kennedy F, Kibbler H, McPhillips P, Elias E, Dusheiko G. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996; 348: 1212-1215
72. Durlik M, Lewandowska D. Lamivudine therapy for chronic hepatitis B in renal transplant recipients. Eur J Gastroenterol Hepatol 2004; 16: 1261-1264.
73. Rostaing L, Henry S, Cisterne JM, Duffaut M, Icart J, Durand D. Efficacy and safety of lamivudine on replication of recurrent hepatitis B after cadaveric renal transplantation. Transplantation 1997; 64: 1624-1627.
74. Jung YO, Lee YS, Yang WS, Han DJ, Park JS, Park SK. Treatment of chronic hepatitis B with lamivudine in renal transplant recipients. Transplantation 1998; 66: 733-737.
75. Fontaine H, Thiers V, Chrétien Y, Zylberberg H, Poupon RE, Bréchot C, Legendre C, Kreis H, Pol S. HBV genotypic resistance to lamivudine in kidney recipients and hemodialyzed patients. Transplantation 2000; 69: 2090-2094.
76. Lewandowska D, Durlik M, Kukula K, Cieciura T, Ciecierski R, Walewska-Zielecka B, Szmidt J, Rowinski W, Lao M. Treatment of chronic hepatitis B with lamivudine in renal allograft recipients. Transplant Proc 2000; 32: 1369-1370.
77. Antoine C, Landau A, Menoyo V, Duong JP, Duboust A, Glotz D. Efficacy and safety of lamivudine in renal transplant patients with chronic hepatitis B. Transplant Proc 2000; 32: 384-385.
78. Tsai MK, Lai MY, Hu RH, Lee CJ, Lee PH. Managing hepatitis B reactivation in renal transplant recipients: a 12-year review with emphasis on early detection and early use of lamivudine. Transplant Proc 2000; 32: 1935-1936.
79. Mosconi G, Scolari MP, Manna C, Canova C, Cristino S, Campieri C, Liviano D'Arcangelo G, Morelli C, Faenza A, Stefoni S. Lamivudine in recurrent hepatitis B after renal transplantation. Transplant Proc 2001; 33: 1873-1874.
80. Kletzmayr J, Watschinger B, Müller C, Demetriou D, Puchhammer-Stöckl E, Ferenci P, Kovarik J. Twelve months of lamivudine treatment for chronic hepatitis B virus infection in renal transplant recipients. Transplantation 2000; 70: 1404-1407.
81. Han DJ, Kim TH, Park SK, Lee SK, Kim SB, Yang WS, Park JS, Jung JG, Yu ES, Kim SC. Results on preemptive or prophylactic treatment of lamivudine in HBsAg (+) renal allograft recipients: comparison with salvage treatment after hepatic dysfunction with HBV recurrence. Transplantation 2001; 71: 387-394.
82. Lee WC, Wu MJ, Cheng CH, Chen CH, Shu KH, Lian JD. Lamivudine is effective for the treatment of reactivation of hepatitis B virus and fulminant hepatic failure in renal transplant recipients. Am J Kidney Dis 2001; 38: 1074-1081.
83. Park SK, Yang WS, Lee YS, Jung HH, Chang JW, Choi HJ, Han DJ, Park JS. Outcome of renal transplantation in hepatitis B surface antigen-positive patients after introduction of lamivudine. Nephrol Dial Transplant 2001; 16: 2222-2228.
84. Fabrizi F, Dulai G, Dixit V, Bunnapradist S, Martin P. Lamivudine for the treatment of hepatitis B virus-related liver disease after renal transplantation: meta-analysis of clinical trials. Transplantation 2004; 77: 859-864.
85. Perrillo R, Hann HW, Mutimer D, Willems B, Leung N, Lee WM, Moorat A, Gardner S, Woessner M, Bourne E, Brosgart CL, Schiff E. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004; 126: 81-90.
86. Benhamou Y, Bochet M, Thibault V, Calvez V, Fievet MH, Vig P, Gibbs CS, Brosgart C, Fry J, Namini H, Katlama C, Poynard T. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet 2001; 358: 718-723.
87. Schiff ER, Lai CL, Hadziyannis S, Neuhaus P, Terrault N, Colombo M, Tillmann HL, Samuel D, Zeuzem S, Lilly L, Rendina M, Villeneuve JP, Lama N, James C, Wulfsohn MS, Namini H, Westland C, Xiong S, Choy GS, Van Doren S, Fry J, Brosgart CL. Adefovir dipivoxil therapy for lamivudineresistant hepatitis B in pre-and post-liver transplantation patients. Hepatology 2003; 38: 1419-1427.
88. Perazella MA. Drug-induced renal failure: update on new medications and unique mechanisms of nephrotoxicity. Am J Med Sci 2003; 325: 349-362.
89. Izzedine H, Launay-Vacher V, Deray G. Antiviral druginduced nephrotoxicity. Am J Kidney Dis 2005; 45: 804-817.
90. Fontaine H, Vallet-Pichard A, Chaix ML, Currie G, Serpaggi J, Verkarre V, Varaut A, Morales E, Nalpas B, Brosgart C, Pol S. Efficacy and safety of adefovir dipivoxil in kidney recipients, hemodialysis patients, and patients with renal insufficiency. Transplantation 2005; 80: 1086-1092.
91. Kamar N, Huart A, Tack I, Alric L, Izopet J, Rostaing L. Renal side effects of adefovir in hepatitis B virus-(HBV) positive kidney allograft recipients. Clin Nephrol 2009; 71: 36-42.
92. Kamar N, Milioto O, Alric L, El Kahwaji L, Cointault O, Lavayssière L, Sauné K, Izopet J, Rostaing L. Entecavir therapy for adefovir-resistant hepatitis B virus infection in kidney and liver allograft recipients. Transplantation 2008; 86: 611-614.
93. Lok AS, Zoulim F, Locarnini S, Bartholomeusz A, Ghany MG, Pawlotsky JM, Liaw YF, Mizokami M, Kuiken C. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 2007; 46: 254-265.
94. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-1531.
95. Thabut D, Thibault V, Bernard-Chabert B, Mouquet C, Di Martino V, Le Calvez S, Opolon P, Benhamou Y, Bitker MO, Poynard T. Long-term therapy with lamivudine in renal transplant recipients with chronic hepatitis B. Eur J Gastroenterol Hepatol 2004; 16: 1367-1373.
96. Kamar N, Sandres-Saune K, Ribes D, Duffaut M, Selves J, Durand D, Izopet J, Rostaing L. Effects of long-term lamivudine therapy in renal-transplant patients. J Clin Virol 2004; 31: 298-303.
97. Chan TM, Tse KC, Tang CS, Lai KN, Ho SK. Prospective study on lamivudine-resistant hepatitis B in renal allograft recipients. Am J Transplant 2004; 4: 1103-1109.
98. Keeffe EB, Zeuzem S, Koff RS, Dieterich DT, Esteban-Mur R, Gane EJ, Jacobson IM, Lim SG, Naoumov N, Marcellin P, Piratvisuth T, Zoulim F. Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 2007; 5: 890-897.
99. Huang YW, Liu CJ, Lai MY, Lee PH, Tsai MK, Wang SS, Lai MK, Kao JH. Discontinuation of lamivudine treatment for hepatitis flare after kidney or heart transplantation in hepatitis B surface antigen-positive patients: A retrospective case series. Clin Ther 2006; 28: 1327-1334.
100. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-539.